A great Q&A video with Philip Daffas. At around the 15m 30s mark, 'why raise capital recently when PCK still have enough capital?' Simplified answer, it will see PCK till end of 2023 when many key milestones will be hit. One of them being FDA approval.
Meanwhile, PainChek is being integrated into various partners' systems who are all vying for market share. The thing is, they will act as a reseller for PainChek as well. So which ever partner wins a contract, PainChek will be sold by them as well. Win/win scenario for PCK all the way.
Also, FDA wants to find a pain assessment system for infant and children and went to Duke University in Canada for help. And guess who Duke University approached? There is only ONE digital pain assessment tool available and Duke University duly approached PCK for help.
After viewing this video, I am now even more confident that my 2025 target will be met. Especially if all those key milestones are hit by end of 2023 as planned by PD. And once again, I re-iterate. PainChek Adult and Infant are the only digital pain assessment and pain management solution available out there. So when you need a digital pain system, who are you gonna call? PainChek, of course.
Good luck all and be happy
PCK Price at posting:
2.8¢ Sentiment: Buy Disclosure: Held
